Abstract
The RAS gene family, comprising KRAS, NRAS, and HRAS, is the most frequently mutated in cancers, with KRAS mutations accounting for approximately 75% of these cases. These mutations play a crucial role in the development of lung, colorectal, and pancreatic cancers, all of which have high mortality rates, prompting a decades-long search for effective KRAS protein inhibitors. However, due t…